Opinion

Video

Patient Case 1: A Sixty-Five-Year-Old Man With Prostate Cancer

Author(s):

Neal Shore, MD, FACS

Neal Shore, MD, FACS, discusses the progress of a 65-year-old patient with mCRPC through various treatments and evaluation for Lutetium-177 therapy based on his PSMA PET scan and MRI.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Treatment Considerations for PSMA-Positive mCRPC Patients
      Treatment Considerations for PSMA-Positive mCRPC Patients
      Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging
      Advancing Prostate Cancer Treatment With Lutetium 617 and PSMA PET Imaging
      Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials
      Sequencing Treatment and Optimizing Care in mCRPC: Insights From VISION and TheraP Trials
      PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials
      PSMA PET Imaging and Radioligand Therapy in mCRPC: Insights From VISION and TheraP Trials
      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.